US open: Dow heads south as tariffs remain in focus
Major indices were in the red early on Tuesday as investors digested a report from the Washington Post that the White House ...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...
Trump unlikely to specify any pharma tariffs in ‘Liberation Day’ announcement: Reuters
Trump's Liberation Day tariff plans spare pharmaceuticals for now, with Big Pharma lobbying for gradual measures. Read more ...
The Pharma Letter6h
EC refers lecanemab decision to Appeal Committee
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...
Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years
For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...
Biotech layoff tracker: 21 companies cut 1,000 jobs in Q1 2025
The Business Journal found 21 Massachusetts life sciences companies announced layoffs impacting at least 1,000 employees ...
Explore more
American Century Companies Inc. Sells 101,604 Shares of Biogen Inc. (NASDAQ:BIIB)
American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...
Biogen Inc. stock underperforms Monday when compared to competitors
Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...